Literature DB >> 26854925

ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.

Rikke Olesen, Michael D Swanson, Martina Kovarova, Tomonori Nochi, Morgan Chateau, Jenna B Honeycutt, Julie M Long, Paul W Denton, Michael G Hudgens, Amy Richardson, Martin Tolstrup, Lars Østergaard, Angela Wahl, J Victor Garcia.   

Abstract

The recently completed HIV prevention trials network study 052 is a landmark collaboration demonstrating that HIV transmission in discordant couples can be dramatically reduced by treating the infected individual with antiretroviral therapy (ART). However, the cellular and virological events that occur in the female reproductive tract (FRT) during ART that result in such a drastic decrease in transmission were not studied and remain unknown. Here, we implemented an in vivo model of ART in BM/liver/thymus (BLT) humanized mice in order to better understand the ability of ART to prevent secondary HIV transmission. We demonstrated that the entire FRT of BLT mice is reconstituted with human CD4+ cells that are shed into cervicovaginal secretions (CVS). A high percentage of the CD4+ T cells in the FRT and CVS expressed CCR5 and therefore are potential HIV target cells. Infection with HIV increased the numbers of CD4+ and CD8+ T cells in CVS of BLT mice. Furthermore, HIV was present in CVS during infection. Finally, we evaluated the effect of ART on HIV levels in the FRT and CVS and demonstrated that ART can efficiently suppress cell-free HIV-RNA in CVS, despite residual levels of HIV-RNA+ cells in both the FRT and CVS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26854925      PMCID: PMC4767352          DOI: 10.1172/JCI64212

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  83 in total

1.  Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding.

Authors:  Susan M Graham; Sarah E Holte; Norbert M Peshu; Barbra A Richardson; Dana D Panteleeff; Walter G Jaoko; Jeckoniah O Ndinya-Achola; Kishorchandra N Mandaliya; Julie M Overbaugh; R Scott McClelland
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

2.  Inefficient vaginal transmission of tenofovir-resistant HIV-1.

Authors:  Morgan Chateau; Michael D Swanson; J Victor Garcia
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

3.  T-lymphocyte profile and total and virus-specific immunoglobulin concentrations in the cervix of HIV-1-infected women.

Authors:  Alison J Quayle; Athena P Kourtis; Susan Cu-Uvin; Joseph A Politch; Huixia Yang; Frederick P Bowman; Meha Shah; Deborah J Anderson; Peggy Crowley-Nowick; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2007-03-01       Impact factor: 3.731

4.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

7.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

8.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

9.  Phenotypic properties of transmitted founder HIV-1.

Authors:  Nicholas F Parrish; Feng Gao; Hui Li; Elena E Giorgi; Hannah J Barbian; Erica H Parrish; Lara Zajic; Shilpa S Iyer; Julie M Decker; Amit Kumar; Bhavna Hora; Anna Berg; Fangping Cai; Jennifer Hopper; Thomas N Denny; Haitao Ding; Christina Ochsenbauer; John C Kappes; Rachel P Galimidi; Anthony P West; Pamela J Bjorkman; Craig B Wilen; Robert W Doms; Meagan O'Brien; Nina Bhardwaj; Persephone Borrow; Barton F Haynes; Mark Muldoon; James P Theiler; Bette Korber; George M Shaw; Beatrice H Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-29       Impact factor: 11.205

10.  Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.

Authors:  Florian Hladik; Polachai Sakchalathorn; Lamar Ballweber; Gretchen Lentz; Michael Fialkow; David Eschenbach; M Juliana McElrath
Journal:  Immunity       Date:  2007-02       Impact factor: 31.745

View more
  16 in total

1.  Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa.

Authors:  Maud Deruaz; Thomas T Murooka; Sophina Ji; Marc A Gavin; Vladimir D Vrbanac; Judy Lieberman; Andrew M Tager; Thorsten R Mempel; Andrew D Luster
Journal:  JCI Insight       Date:  2017-04-06

2.  HIV co-infection augments EBV-induced tumorigenesis in vivo.

Authors:  Christopher B Whitehurst; Monica Rizk; Adonay Teklezghi; Rae Ann Spagnuolo; Joseph S Pagano; Angela Wahl
Journal:  Front Virol       Date:  2022-03-11

Review 3.  Humanized mice for HIV and AIDS research.

Authors:  J Victor Garcia
Journal:  Curr Opin Virol       Date:  2016-07-19       Impact factor: 7.090

Review 4.  Humanized Mouse Models of Clinical Disease.

Authors:  Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

5.  T cells establish and maintain CNS viral infection in HIV-infected humanized mice.

Authors:  Jenna B Honeycutt; Baolin Liao; Christopher C Nixon; Rachel A Cleary; William O Thayer; Shayla L Birath; Michael D Swanson; Patricia Sheridan; Oksana Zakharova; Francesca Prince; JoAnn Kuruc; Cynthia L Gay; Chris Evans; Joseph J Eron; Angela Wahl; J Victor Garcia
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

Review 6.  So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Authors:  Adam J Kleinman; Ivona Pandrea; Cristian Apetrei
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

7.  Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA.

Authors:  Uma Shanmugasundaram; Martina Kovarova; Phong T Ho; Nathaniel Schramm; Angela Wahl; Michael A Parniak; J Victor Garcia
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

8.  Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.

Authors:  Angela Wahl; Phong T Ho; Paul W Denton; Katy L Garrett; Michael G Hudgens; Glenn Swartz; Cynthia O'Neill; Fulvia Veronese; Angela D Kashuba; J Victor Garcia
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

9.  Frequency of Human CD45+ Target Cells is a Key Determinant of Intravaginal HIV-1 Infection in Humanized Mice.

Authors:  Philip V Nguyen; Jocelyn M Wessels; Kristen Mueller; Fatemeh Vahedi; Varun Anipindi; Chris P Verschoor; Marianne Chew; Alexandre Deshiere; Uladzimir Karniychuk; Tony Mazzulli; Michel J Tremblay; Ali A Ashkar; Charu Kaushic
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

Review 10.  Humanized Mouse Models for the Study of Infection and Pathogenesis of Human Viruses.

Authors:  Fritz Lai; Qingfeng Chen
Journal:  Viruses       Date:  2018-11-17       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.